Leukemia and Lymphoma

Better Knowledge Needed of Unmet Needs of Cancer Survivors

September 23rd 2021, 1:30pm


Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.

BTK Inhibition in CLL: Successes and Challenges

September 19th 2021, 7:30pm


A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).

Zanubrutinib Gains Accelerated Approval in R/R Marginal Zone Lymphoma

September 15th 2021, 1:54pm


This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.

Posters Highlight Need for Psychosocial Support in Adolescent Survivors of Childhood Leukemia

September 14th 2021, 6:00pm


Two posters being presented at the European Society for Medical Oncology Congress 2021 highlighted the need to provide long-term psychosocial support for adolescents who survive childhood leukemia.

Researchers Find Insight Into Risk of Developing AML

September 10th 2021, 7:45pm


In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

Data Support Once-Daily Dosing of Zanubrutinib for MCL

September 9th 2021, 11:10am


Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.

Ongoing Research Aims to Elucidate Underlying Drivers of HCL

September 6th 2021, 2:15pm


Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.

Study Examines Treatment Link to Transplant Complication in GVHD

September 6th 2021, 1:00pm


Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

FDA Approves Zanubrutinib in Adults With Waldenström Macroglobulinemia

September 2nd 2021, 4:25pm


The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.

Researchers Identify Potential Approach to Overcoming CLL CAR T-Cell Resistance

September 1st 2021, 2:00pm


The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.